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The aims of this study were to i) reveal the population pharmacokinetics; and ii) assess the probability of
target attainment (PTA) and cumulative fraction of response (CFR) (deﬁned as the expected population
PTA for a speciﬁc drug dose and a speciﬁc population of microorganisms) of imipenem in febrile neu-
tropenic patients with bacteraemia. Ten patients were randomised into two groups: Group I received a
0.5-h infusion of 0.5 g of imipenem every 6 h (q6h) for 8 doses; and Group II received a 4-h infusion of
0.5 g q6h for 8 doses. A Monte Carlo simulation was performed to determine the PTA. The volume of
distribution and total clearance of imipenem were 20.78 ± 1.35 l and 23.19 ± 1.34 l/h, respectively. Only
a 4-h infusion of 1 g q6h regimen achieved a PTA >93% for 80% T>MIC for a MIC of 2 mg/ml. A 4-h infusion
of all simulated regimens and a 0.5-h infusion of 0.5 g q6h and 1 g q6h achieved targets (CFR  90%)
against Escherichia coli and Klebsiella spp. However, against Pseudomonas aeruginosa and Acinetobacter
spp., no regimens achieved their targets. In conclusion, the results indicate that a higher than manu-
facturer's dosage recommendation is required to maximize the activity of imipenem.
© 2015 Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society.1. Introduction
Carbapenems, a class of antimicrobial agents providing a
broad spectrum of activity against Gram-negative, Gram-positive
and anaerobic bacteria, are widely prescribed in critically ill pa-
tients with severe infections. Imipenem, a carbapenem antibiotic,
is one of the most crucial antibiotics used for coverage of some
highly resistant pathogens (1). In common with other b-lactams,
this agent exhibits primarily time-dependent antimicrobial ac-
tivity and the pharmacokinetics/pharmacodynamics (PK/PD) in-
dex that best predicts the in vivo antimicrobial activity is the
exposure time during which the plasma concentration remains
above the minimum inhibitory concentration (T>MIC) of the
pathogens (2,3).66 74 429385.
uratanasirikul).
acological Society.
r B.V. on behalf of Japanese PharmIn critically ill patients with severe sepsis, the early use of an
appropriate antimicrobial agent in terms of spectrum of antimi-
crobial activity are known to be the major factors for successful
treatment, leading to a lower mortality rate for patients than less
efﬁcacious treatment regimens (4). Moreover, altered PK patterns
have been found with several hydrophilic antimicrobial agents
used in critically ill patients with febrile neutropenia when
compared with healthy subjects, resulting in ﬂuctuation of the
plasma concentrations of the drug and thus affecting the achieve-
ment of the desired pharmacodynamic targets for effective anti-
microbial therapy (5,6). Another previous study also found that the
total clearance (CL) of imipenem was signiﬁcantly lower and the
volume of distribution (Vd) signiﬁcantly larger in this patient
population than in normal volunteer populations (7). Therefore, the
aims of this study were to i) study the population PK of imipenem,
and ii) assess the probability of target attainment (PTA) and
cumulative fraction of response (CFR) of imipenem in serious
bacteraemia in immunocompromised patients with febrile neu-
tropenia in order to optimize a dosage regimen.acological Society.
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2.1. Subjects
The study was conducted in patients with febrile neutropenia
and bacteraemia. Patients were eligible for the study if theymet the
following criteria: (i) age>18 years; (ii) body temperature38.3 C;
(iii) neutrophil count <500 cells/ml; and (iv) having bacteraemia,
conﬁrmed by at least one positive blood culture. Patients were
excluded from the study if they were pregnant or in circulatory
shock (deﬁned as a systolic blood pressure of <90 mmHg and poor
tissue perfusion) or had documented hypersensitivity to imipenem
or an estimated creatinine clearance (CLCr) (determined by the
CockcrofteGault method) (8) of <50 ml/min. MICs were deter-
mined by E test. The protocol for the study was approved by the
Ethics Committee of Songklanagarind Hospital and written
informed consent was obtained from each subject before
enrolment.
2.2. Drugs and chemicals
Imipenem (Tienam®) was purchased from MSD, Thailand. Imi-
penem standard powder was generously donated by Merck & Co,
Inc., USA. All the solvents were of high-performance liquid chro-
matography (HPLC) grade.
2.3. Study design
The patients were allocated by simple randomization into two
groups using blinded opaque envelope selection. Group I received a
0.5-h infusion of 0.5 g of imipenem diluted in 100 ml of normal
saline solution via an infusion pump at a constant ﬂow rate every
6 h (q6h) for 8 doses, and Group II received a 4-h infusion of 0.5 g of
imipenem diluted in 100 ml of normal saline solution via an infu-
sion pump at a constant ﬂow rate q6h for 8 doses. A Monte Carlo
simulation (MCS) was performed to predict the PTAs determining
the efﬁcacy of various dosage regimens (0.5 g q6h,1 g q6h, 0.5 g q8h
and 1 g q8h) of imipenem. All imipenem doses were given at room
temperature (32e37 C), and after completion of the 2-day study
regimen, all patients were still treated with imipenem for 11 more
days to complete their full 14-day course of treatment.
2.4. Blood sampling
The imipenem PK studies were carried out during administra-
tion of the eighth dose of each regimen. Blood samples (ca. 3 ml)
were obtained by direct venipuncture at the following times:
shortly before beginning the dosage regimens (time 0) and then at
0.25, 0.5, 0.75, 1, 2, 3, 4, 5 and 6 h after the eighth dose of a 0.5-h
infusion and shortly before beginning the dosage regimens (time
0) and then at 0.5,1, 2, 3, 4, 4.5, 5, 5.5 and 6 h after the eighth dose of
a 4-h infusion. All blood samples were transferred to a heparinised
tube, immediately stored on ice, and centrifuged at 1000 g at 4 C
for 10 min within 5 min. An equal volume of stabilising solution
[0.5 M 3-(N-morpholino) propanesulfonic acid (MOPS)/water/
ethylene glycol, 2:1:1, v/v/v] was added to each plasma sample, and
the mixture was then vortexed and stored at 80 C until analysis
within 1 week.
2.5. Imipenem assay
This assay was used for measuring imipenem concentrations
only, not for cilastatin concentrations. The concentrations of imi-
penem were determined by reversed-phase HPLC. The samples
were prepared by the method of Garcia-Capdevila et al (9). Brieﬂy,250 ml of the stabilizing solutionwas added to 250 ml of the sample.
Mixtures were then subjected to ultraﬁltration, using Ultrafree®-
MC Centrifugal Filter Units, for 10 min at 6000 g. An aliquot of the
sample (10 ml) was injected, using an automated injection system
(Waters 717 plus Autosampler, Waters Associates, Milford, MA,
USA), onto a Nova-Pak C18 column (Waters Associates). The mobile
phase was 0.2 M borate buffer, pH 7.2, at a ﬂow rate of 1 ml/min.
The column efﬂuent was monitored by UV detection (Waters 486,
Waters Associates) at 300 nm. The peaks were recorded and inte-
grated on a Waters 746 Data Module (Waters Associates). The limit
of detection of imipenem was 0.125 mg/ml. The intra-assay repro-
ducibility values characterized by coefﬁcients of variation (CVs)
were 1.84%, 0.02% and 0.95% for samples containing 1, 10 and
100 mg/ml, respectively. The inter-assay reproducibility precision
values, calculated by CVs, were 2.60%, 4.75% and 2.18% for samples
containing 1, 10 and 100 mg/ml, respectively.
2.6. PK analysis & Monte Carlo simulation
The 2-compartment model could not consistently describe the
whole concentration-time proﬁle obtained. We found that the 3-
compartment infusion model could consistently describe the imi-
penem concentration-time proﬁle. The differential equations
describing the 3-compartment model were solved numerically by
Taylor series expansion (10), using Visual Basic language in
Microsoft Excel (Microsoft Excel 2003, Microsoft Corp). The sum-
mation of inﬁnite series was calculated until converge. The method
was validated to be consistent with Runge-Kutta order 4 method
(10). Taylor series method is used to achieve better numerical sta-
bility with high pharmacokinetic rate parameters (i.e., stiff differ-
ential equations). PK parameters were obtained by nonlinear
regression. The objective function to be minimized is the sum of
square errors of logarithmic transformed data. The reason for log-
arithmic transformation is to enhance the reliability of the whole
distribution phase which was used extensively in computing time
above MIC. The optimization method is random heuristic optimi-
zation (11,12). The search parameters were permitted to random
walk around the previous best result to achieve improved ﬁt and
repeat this process until converge. The method was repeated with
different initial conditions to ascertain global convergence.
The Monte Carlo simulation (MCS) used in this study was
written in the Basic language using the Quick Basic 3.0 compiler
(Microsoft Corp) to calculate concentration-time proﬁles. Box-
Muller Transformation was used to simulate the log-normal PK
parameters (13). A Choleski decomposition matrix, computed from
covariate matrix (14), was solved (and validated to be working
properly) in Microsoft Excel was used for simulating new PK pa-
rameters dataset with the same covariates. All simulated parame-
ters were validated for average, standard deviation and covariance
to ensure therewere no statistically signiﬁcant differences between
the simulated parameters and the actual parameters (Appendix A).
The MCS was performed using at least 10,000 sets of simulated
parameters to calculate the % target attainment at 40% and 80%
T>MIC.
2.7. Minimum inhibitory concentration distributions and
cumulative fraction of response
MIC distributions were derived from imipenem MIC50 and
MIC90 (MICs for 50% and 90% of the organisms, respectively) and
MIC ranges obtained from the European Committee on Antimi-
crobial Susceptibility Testing (EUCAST; updated 2 Oct 2013) for
Escherichia coli, Klebsiella spp., Pseudomonas aeruginosa and Acine-
tobacter spp. isolates. MIC distributions were estimated from 16667
strains of E. coli, 29483 strains of Klebsiella spp., 64225 strains of
Table 2
Pharmacokinetic (PK) parameters of imipenem in 10 febrile neutropenic patients
following administration by 0.5-h and 4-h infusions.
Parameter Geometric mean Geometric S.D. Median (95%CI)
k12 (/h) 0.32 2.29 0.42 (0.11e0.84)
k21 (/h) 2.10 2.22 3.35 (0.67e4.99)
k13 (/h) 1.02 2.22 1.00 (0.34e2.17)
k31 (/h) 1.25 2.46 1.59 (0.59e5.67)
ke (/h) 1.12 1.37 1.09 (0.83e1.30)
CL (l/h) 23.19 1.34 24.51 (16.43e35.26)
Vd (l) 20.78 1.35 18.81 (13.26e32.23)
S.D., standard deviation; CI, conﬁdence interval; k12, intercompartmental transfer
rate constant from compartment X1 to X2; k21, intercompartmental transfer rate
constant from compartment X2 to X1; k13, intercompartmental transfer rate con-
stant from compartment X1 to X3; k31, intercompartmental transfer rate constant
from compartment X3 to X1; ke, elimination rate constant from X1; CL, total clear-
ance; Vd, volume of distribution.
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(deﬁned as the expected population PTA for a speciﬁc drug dose
and a speciﬁc population of microorganisms) were determined for
each regimen against each population of E. coli, Klebsiella spp.,
P. aeruginosa and Acinetobacter spp. The optimal CFRs were deﬁned
as 90%.
3. Results
Ten febrile neutropenic patients were enrolled in the study
(six males and four females), with a mean ± S.D. age of
38.8 ± 16.96 years (range 18e68 years) and a mean ± S.D. body
weight of 58.35 ± 15.74 kg (range 27.7e87 kg). The characteris-
tics of all patients and the MICs of imipenem for the isolated
pathogens are shown in Table 1. The population PK parameters of
imipenem are shown in Table 2. The mean ± S.D. of Vd and CL of
imipenem in these patients were 20.78 ± 1.35 l and
23.19 ± 1.34 l/h, respectively. None of the tested covariates had
any identiﬁable inﬂuence on the PK parameters (Appendix A).
The PTAs for the 0.5-h and 4-h infusion regimens of imipenem
achieving 40% T>MIC and 80% T>MIC at speciﬁc MICs are shown in
Table 3 and Fig. 1. For pathogens with a MIC of 2 mg/ml, the PTAs
of achieving 40% T>MIC following administration of imipenem by
a 0.5-h infusion of 0.5 g q6h, 1 g q6h, 0.5 g q8h and 1 g q8h were
69.68%, 97.15%, 37.22% and 87.31%, respectively and the PTAs of
achieving 40% T>MIC following administration of imipenem by a
4-h infusion of 0.5 g q6h, 1 g q6h, 0.5 g q8h and 1 g q8h were
96.63%, 99.97%, 90.79% and 99.93%, respectively. For pathogens
with a MIC of 4 mg/ml, the PTAs of achieving 40% T>MIC following
administration of imipenem by a 4-h infusion of 0.5 g q6h, 1 g
q6h, 0.5 g q8h and 1 g q8h were 29.07%, 96.58%, 12.12% and
91.11%, respectively. For pathogens with a MIC of 1 mg/ml, the
PTAs of achieving 80% T>MIC following administration of imipe-
nem by a 4-h infusion of 0.5 g q6h, 1 g q6h, 0.5 g q8h and 1 g q8h
were 93.56%, 99.86%, 49.33% and 89.08%, respectively. For path-
ogens with a MIC of 2 mg/ml, the PTAs of achieving 80% T>MIC
following administration of imipenem by a 4-h infusion of 0.5 g
q6h, 1 g q6h, 0.5 g q8h and 1 g q8h were 34.77%, 93.60%, 4.45%
and 49.28%, respectively. Assessment of CFR for the patients who
achieved 40% T>MIC and 80% T>MIC with the imipenem regimens
against E. coli, Klebsiella spp., P. aeruginosa and Acinetobacter spp.
are shown in Table 4. The predicted CFRs for PTA achieving aTable 1
Characteristics of the 10 febrile neutropenic patients.
Patient Age
(years)
Sex Weight
(kg)
CLCr
(ml/min)
Diagnosis Neutrophil
count
(cells/ml)
Pathogen
1 43 F 27.7 155.49 AA 0 Enterobacter cloa
2 68 M 87 113.77 PTCL 0 Escherichia coli
3 52 M 59.1 103.19 LBL 0 Klebsiella pneum
4 19 F 48.2 186.09 AML 44 Klebsiella pneum
5 23 M 59 100.92 AML 0 Klebsiella pneum
6 18 F 73.8 241.57 AML 0 Escherichia coli
7 39 M 64.2 95.81 ALL 0 Pseudomonas
aeruginosa
8 59 F 50.7 51.58 MM 0 Escherichia coli
9 32 M 60.75 97.98 AML 0 Klebsiella pneum
10 35 M 53 92.01 AML 0 Escherichia coli
CLCr, creatinine clearance; MIC, minimum inhibitory concentration; Fluid balance, ﬂuid
aplastic anemia; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; LBL, lytarget of 40% T>MIC and 80% T>MIC for E. coli following adminis-
tration of imipenem by all simulated regimens were >90%. The
predicted CFRs for PTA achieving a target of 40% T>MIC and 80%
T>MIC for Klebsiella spp. following administration of imipenem by
all simulated regimens were >90%, except a 0.5 h infusion of 0.5 g
q8h and 1 g q8h. All regimens were well tolerated and there were
no adverse events.
4. Discussion
We found that the values of Vd and CL of imipenemwere high in
serious bacteraemia in immunocompromised patients with febrile
neutropenia. A high dosage regimen of a prolonged infusion of 1 g
q6h of imipenem may be required for the effective treatment of
bacteraemia with pathogens less susceptible to imipenem in this
patient population.
Altered pathophysiological conditions in critically ill patients
resulting in variations in PK are important factors determining the
therapeutic success of antimicrobial agents, particularly hydro-
philic antibiotics. For critically ill patients with severe sepsis, the
increase of Vd caused by the presence of extensive ﬂuid extrava-
sation as well as enhanced CL result in decreased drug concentra-
tions (15,16). Therefore, a higher dosage of antimicrobial agents
than standard dose recommendationsmay be required for coverage
of the causative organisms. In addition, a previous study in febrileMIC
(mg/ml)
Fluid balance
(ml)
Concomitant medications
cae 0.25 þ4500 Vancomycin
0.125 þ3526 Filgrastim, doxorubicin, cyclophosphamide,
vincristine, prednisolone
oniae 0.094 þ1360 Vincristine, doxorubicin, mesna, dexamethasone
oniae 0.25 þ1810 Cytarabine, idarubicin, ﬁlgrastim
oniae 0.125 þ8346 Amphotericin B, vancomycin, ﬁlgrastim,
cytarabine, idarubicin
0.125 þ1825 Vancomycin, ﬁlgrastim, cytarabine
0.75 2800 Co-trimoxazole, dexamethasone, cytarabine,
vincristine
0.25 þ1990 Co-trimoxazole, dexamethasone,
cyclophosphamide, doxorubicin, vincristine,
mesna, ﬁlgrastim
oniae 0.19 þ4916 Vancomycin, amphotericin B, ﬁlgrastim,
cytarabine
0.125 þ3150 Amikacin, ceftazidime, co-trimoxazole,
ﬁlgrastim, acyclovir, cytarabine
intake minus ﬂuid output for 2 days during the administration of imipenem; AA,
mphoblastic lymphoma; PTCL, peripheral T-cell lymphoma; MM, multiple myeloma.
Table 3
Probability of target attainment (PTA) for imipenem regimens achieving 40% T>MIC and 80% T>MIC in 10 febrile neutropenic patients following administration by 0.5-h and 4-h
infusions.
MIC (mg/ml) PTA 40% T>MIC PTA 80% T>MIC
0.5-h infusion 4-h infusion 0.5-h infusion 4-h infusion
q6h q8h q6h q8h q6h q8h q6h q8h
0.5 g 1 g 0.5 g 1 g 0.5 g 1 g 0.5 g 1 g 0.5 g 1 g 0.5 g 1 g 0.5 g 1 g 0.5 g 1 g
0.0625 100 100 100 100 100 100 100 100 99.87 99.97 96.75 99.08 100 100 100 100
0.125 100 100 100 100 100 100 100 100 99.15 99.87 90.41 96.77 100 100 99.88 99.98
0.25 99.99 100 99.91 100 100 100 100 100 95.45 99.04 76.11 90.44 100 100 98.56 99.84
0.5 99.86 99.98 98.90 99.91 100 100 100 100 81.81 95.41 49.80 76.18 99.88 99.99 88.92 98.64
1 97.26 99.87 87.08 98.90 99.97 100 99.94 100 43.92 81.14 15.14 49.96 93.56 99.86 49.33 89.08
2 69.68 97.15 37.22 87.31 96.63 99.97 90.79 99.93 5.10 43.38 0.61 15.62 34.77 93.60 4.45 49.28
4 10.97 70.18 1.78 37.68 29.07 96.58 12.12 91.11 0.03 5.17 0.004 0.66 0.47 34.70 0.01 4.45
8 0.03 10.89 0.004 1.76 0.10 29.02 0 12.42 0 0.04 0 0 0 0.47 0 0.003
MIC, minimum inhibitory concentration; T>MIC, time that concentration in tissue and serum are above the MIC; q6h, every 6 h; q8h, every 8 h.
Fig. 1. Probability of target attainment (PTA) for imipenem regimens achieving (A) 40%
T>MIC and (B) 80% T>MIC at speciﬁc minimum inhibitory concentrations (MICs) in 10
febrile neutropenic patients after administration of a 0.5-h infusion of 0.5 g q6h (open
square); a 0.5-h infusion of 1 g q6h (open diamond); a 0.5-h infusion of 0.5 g q8h (open
triangle); a 0.5-h infusion of 1 g q8h (open circle); a 4-h infusion of 0.5 g q6h (close
square); a 4-h infusion of 1 g q6h (close diamond); a 4-h infusion of 0.5 g q8h (close
triangle); a 4-h infusion of 1 g q8h (close circle). The broken line represents 90% PTA.
T>MIC, time that concentrations in tissue and serum are above the MIC.
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larger, but the CL was lower than in normal volunteers (7). The
current studywas conducted in life-threatening bacteraemia due to
Gram-negative bacilli infections occurring in febrile neutropenic
patients, most of whom had a positive ﬂuid balance from admin-
istration of large volumes of ﬂuid resuscitation. Moreover, most of
these patients also received a number of concomitant medications
during the imipenem administration, but none of these drugs
affected renal blood ﬂow of the patients. Comparison of the
mean ± S.D. PK parameters between the current study and a pre-
vious study yielded: Vd, 20.78 ± 1.35 versus 9.41 ± 1.44 and CL,
23.19 ± 1.34 versus 7.95 ± 1.04 l/h (17). The values of both Vd and
total CL of imipenem in these patients were signiﬁcantly higher
than the values obtained from a previous study with healthy vol-
unteers (p < 0.001). Moreover, as compared with the results of PK
studies from critically ill patients such as those suffering from burn
or ventilator-associated pneumonia, the values of Vd and CL of
imipenem in our study were still higher than the values obtained
from previous studies (18,19). A possible explanation for these re-
sults is that patients enrolled in this study had an extensive ﬂuid
extravasation and positive ﬂuid balance than those from a previous
study, as all patients in this study had both febrile neutropenia and
severe bacteraemia with Gram-negative bacilli pathogens. Cil-
astatin, a renal dehydropeptidase inhibitor, is coadministered in a
ﬁxed-drug combination with imipenem in a 1:1 ratio for preven-
tion of the degradation of the imipenem, to protect the kidneys
against the toxic metabolite of imipenem. Cilastatin is eliminated
by renal clearance, therefore, serious bacteraemia in febrile neu-
tropenic patients may affect its PK, including enhanced renal
clearance. However, cilastatin has no intrinsic antimicrobial activity
of its own against microorganisms, thus, the therapeutic efﬁcacy of
imipenem/cilastatin depends on the activity of imipenem only (1).
Imipenem is used effectively as a therapy for severe sepsis in
patients with febrile neutropenia (20,21). In tropical countries, the
stability of imipenem is an important consideration when contin-
uous infusion is to be used (22) and our previous study showed that
imipenem remained 91% stable for 4 h at 37

C (unpublished data).
Therefore administration by prolonging the intermittent infusion
may offer an opportunity to increase the T>MIC within the limita-
tions of stability at room temperature. A study in a murine thigh-
infection model has shown that bactericidal activity of carbape-
nems against E. coli and P. aeruginosa is observed when serum drug
concentrations are above the MIC for 40% of the dosing interval
(23). In a previous PD study in patients with pneumonia in an
intensive care unit, the high PTA (90%) for achieving the target of
40% T>MIC was observed at an MIC of 1e2 mg/ml when imipenem
was administered by an intermittent 40 min infusion of 1 g q8h,
Table 4
CFR (percentages) for 0.5-h infusion, 0.5 g q6h; 0.5-h infusion, 1 g q6h; 0.5-h infusion, 0.5 g q8h; 0.5-h infusion, 1 g q8h; 4-h infusion, 0.5 g q6h; 4-h infusion, 1 g q6h; 4-h
infusion, 0.5 g q8h; 4-h infusion, 1 g q8h of imipenem against E. coli, Klebsiella spp., P. aeruginosa and Acinetobacter spp. at PTA achieving 40% and 80% T>MIC in ten febrile
neutropenic patients.
% Susceptiblea CFR for EUCASTb
40% PTA 80% PTA
0.5-h infusion 4-h infusion 0.5-h infusion 4-h infusion
q6h q8h q6h q8h q6h q8h q6h q8h
0.5 g 1 g 0.5 g 1 g 0.5 g 1 g 0.5 g 1 g 0.5 g 1 g 0.5 g 1 g 0.5 g 1 g 0.5 g 1 g
E. coli 99.66 99.39 99.63 98.94 99.55 99.63 99.66 99.59 99.66 94.86 97.86 82.42 92.02 99.09 99.61 97.14 99.01
Klebsiella spp. 99.61 99.25 99.58 98.43 99.45 99.58 99.61 99.53 99.61 91.15 96.95 74.01 87.78 98.86 99.55 94.33 98.50
P. aeruginosa 80.86 67.68 78.21 56.52 73.66 75.36 80.62 73.03 80.24 31.01 55.21 14.43 34.64 58.57 75.09 33.96 59.85
Acinetobacter spp. 78.33 75.09 78.04 70.56 76.98 78.01 78.33 77.45 78.33 57.59 69.06 42.65 56.95 71.32 77.71 60.73 71.89
q6h, every 6 h; q8h, every 8 h.
a Susceptibility determined using 2013 European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoint of imipenem.
b CFR determined using MIC distribution of 2013 EUCAST.
Parameter Actual Simulated
k12ek21 0.178 0.161
k12ek13 0.835 0.844
k12ek31 0.224 0.213
k12eke 0.450 0.433
k12eVd 0.782 0.781
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penem had a 90% PTA for achieving the target of 40% T>MIC at an
MIC of 2e4 mg/ml (19). In the current study, a MCS was performed
to determine the probability of attaining a speciﬁc PD target using
various regimens. The results conﬁrmed that the probabilities of 4-
h infusion regimens achieving their targets of 40% T>MIC and 80%
T>MIC were superior to the probabilities of 0.5-h infusion of imi-
penem regimens, suggesting that a prolonged infusion is a more
efﬁcacious mode of administration of imipenem. The high PTA
achieving 40% T>MIC for MIC of 2 mg/ml was observed when imi-
penem was administered by a prolonged infusion of all regimens.
For pathogens with MICs of 4 mg/ml, the high PTA was achieved
when the dosage of imipenemwas increased to either a 1 g q8h or a
1 g q6h regimen and, moreover, only a 4-h infusion of 1 g q6h
regimen achieved >96% PTA of 40% T>MIC.
Gram-negative bacilli bacteraemia in immunocompromised
patients with febrile neutropenia is a life-threatening infection
with a high mortality rate, therefore an appropriate antibiotic
therapy and optimum dosing regimen are necessary for maximal
bacterial killing. Some experts recommend that for life-threatening
infections, antibiotic concentrations should be maintained over the
MIC for 66 to 100% of the dosing interval to achieve the maximal
antibacterial effect (24,25). In a previous clinical study in febrile
neutropenic patients conducted to investigate the relationship
between the PK/PD index of T>MIC of meropenem and clinical
outcomes, the results clearly demonstrated that an optimum clin-
ical response was shown when the percentages of T>MIC of mer-
openem exceeded 75% of the dosing interval (26). The clinical
breakpoint, as deﬁned by EUCAST, are2 mg/ml for E. coli,2 mg/ml
for Klebsiella spp, 4 mg/ml for P. aeruginosa and 2 mg/ml for
Acinetobacter spp. Our results showed that the high PTAs of
achieving 80% T>MIC for MICs of 1 mg/ml and 2 mg/ml were observed
when imipenemwas administered by 4-h infusions of 0.5 g q6h and
1 g q6h, respectively. Therefore, from these data we recommend
that for the treatment of severe sepsis with pathogens less sus-
ceptible to imipenem in immunocompromised hosts with altered
PK, the imipenem dosage administered by a 4-h infusion should be
increased to a maximum of 1 g q6h. However, the MICs of all iso-
lated pathogens in this study were <1 mg/ml, and, after 14 days of
treatment, blood cultures were negative in all patients. By using the
EUCAST susceptibility patterns to determine the CFR of imipenem
for the target of 40%T>MIC, all regimens achieved targets (CFR90%)
against E. coli and Klebsiella spp., whereas for the target of 80%T>MIC,
only a 4-h infusion of all regimens and a 0.5-h infusion of 0.5 g q6h
and 1 g q6h achieved targets against these pathogens. However,
against P. aeruginosa and Acinetobacter spp., no regimens achieved
their targets.This study had some limitations to be considered. First, the PK
studies of imipenem in this study were performed at a steady state
situation rather than during the early phase of therapy. For critically
ill patients with severe sepsis, the increase of Vd from ﬂuid resus-
citation during the early phase of antibiotic therapy has more in-
ﬂuence on antimicrobial concentrations than at the later steady
state. Second, the results of this study could be difﬁcult to extrap-
olate to other situations because the low body weight of the pa-
tients could have had an effect on Vd and CL. Third, the small
number of patients could be considered a potential limitation.
However, in the absence of data from a larger sample size, a MCS
based on a small number of patients such as in this study can be
instructive in illuminating the effects of different dosing ap-
proaches (27). Fourth, the CockcrofteGault method used for esti-
mating CLCr is known to have certain limitations in severely ill and/
or elderly patients (28,29).
In conclusion, we found that the values of Vd and CL of imipe-
nem were high in serious bacteraemia in immunocompromised
patients with febrile neutropenia. Therefore, for more efﬁcacious
treatment of serious infections in this patient population, we
recommend a high dosage regimen of a prolonged infusion of 1 g
q6h of imipenem may be required.
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Appendix A. Comparison of covariance matrixes between the
actual and simulated pharmacokinetic parameters.
(continued )
Parameter Actual Simulated
k12eCLCr 0.175 0.169
k21ek13 0.008 0.025
k21ek31 0.137 0.155
k21eke 0.458 0.449
k21eVd 0.017 0.001
k21e CLCr 0.026 0.008
k13ek31 0.088 0.088
k13eke 0.576 0.592
k13eVd 0.685 0.700
k13eCLCr 0.084 0.066
k31eke 0.194 0.176
k31eVd 0.354 0.371
k31eCLCr 0.212 0.225
keeVd 0.562 0.578
keeCLCr 0.114 0.113
VdeCLCr 0.444 0.459
AgeeCLCr 0.584 0.598
Ageek12 0.184 0.199
Ageek21 0.070 0.052
Ageek13 0.156 0.170
Ageek31 0.083 0.100
Ageeke 0.338 0.343
AgeeVd 0.061 0.059
BWeCLCr 0.050 0.058
BWek12 0.020 0.002
BWek21 0.297 0.315
BWek13 0.089 0.074
BWek31 0.080 0.098
BWeke 0.009 0.006
BWeVd 0.158 0.173
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